AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35381904 — intervention group
Group type: COMPARATOR
Intervention: PEEP 0 cmH2O
Number of subjects: 25
Study 35381904 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 25
Study 35381904 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 25
Study 34278803 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg once daily
Number of subjects: 90
Study 34278803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 33714847 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelotanserin 80 mg
Number of subjects: 34
Study 33714847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 36115142 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine assessment
Number of subjects: 58
Study 36115142 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 58
Study 36115142 — intervention group
Group type: COMPARATOR
Intervention: Comparison of telemedicine and in-person assessments
Number of subjects: 58
Study 33278897 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal therapy
Number of subjects: 69
Study 33278897 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal therapy + exercises
Number of subjects: 69
Study 33278897 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 69
Study 35753828 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic Wafer Procedure (AWP)
Number of subjects: 60
Study 35753828 — intervention group
Group type: COMPARATOR
Intervention: Ulnar Shortening Osteotomy (USO)
Number of subjects: 60
Study 33482631 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking ≥8 medications
Number of subjects: 439
Study 33482631 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially inappropriate medications (PIMs)
Number of subjects: 439
Study 33482631 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutoff of 5 medications
Number of subjects: 439
Study 33204249 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance Intervention (DI)
Number of subjects: 76
Study 33204249 — intervention group
Group type: COMPARATOR
Intervention: Control (life as usual)
Number of subjects: 76
Study 35762448 — intervention group
Group type: EXPERIMENTAL
Intervention: Cloti‐Xa™ (40 mg/0.4 ml)
Number of subjects: 24
Study 35762448 — intervention group
Group type: COMPARATOR
Intervention: Cloti‐Xa™ and Clexane®
Number of subjects: 24
Study 34728527 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 760
Study 34728527 — intervention group
Group type: COMPARATOR
Intervention: No retroperitoneal node dissection
Number of subjects: 760
Study 32003647 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Exercises (EE)
Number of subjects: 42
Study 32003647 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric + Isometric Exercises (EE + ISO)
Number of subjects: 42
Study 32003647 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic Insertion
Number of subjects: 42
Study 32003647 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic Midportion
Number of subjects: 42
Study 32003647 — intervention group
Group type: COMPARATOR
Intervention: Midportion vs Insertion
Number of subjects: 42
Study 33564120 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) combined with standard chemotherapy
Number of subjects: 85
Study 33564120 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone (control)
Number of subjects: 85
Study 34762724 — intervention group
Group type: EXPERIMENTAL
Intervention: US combined with limited radiography (UR group)
Number of subjects: 50
Study 34762724 — intervention group
Group type: COMPARATOR
Intervention: Radiography only (RO group)
Number of subjects: 50
Study 34762724 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 34762724 — intervention group
Group type: COMPARATOR
Intervention: RO group
Number of subjects: 50
Study 34762724 — intervention group
Group type: EXPERIMENTAL
Intervention: UR group
Number of subjects: 50
Study 33323287 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit strongly trainer‐guided debriefing
Number of subjects: 136
Study 33323287 — intervention group
Group type: COMPARATOR
Intervention: Implicit and weakly guided debriefing
Number of subjects: 136
Study 35183282 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0
Study 35183282 — intervention group
Group type: COMPARATOR
Intervention: Psychosocial counselling
Number of subjects: 0
Study 33674679 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h-split (nocturnal sleep + 90-min afternoon nap)
Number of subjects: 112
Study 33674679 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 h-split (nocturnal sleep + 90-min afternoon nap)
Number of subjects: 112
Study 33674679 — intervention group
Group type: COMPARATOR
Intervention: 8 h-continuous (no afternoon nap)
Number of subjects: 112
Study 33674679 — intervention group
Group type: COMPARATOR
Intervention: 6.5 h-continuous (no afternoon nap)
Number of subjects: 112
Study 33993715 — intervention group
Group type: EXPERIMENTAL
Intervention: eDASA+APP
Number of subjects: 77
Study 35761030 — intervention group
Group type: EXPERIMENTAL
Intervention: Osc+ condition (heart rate variability biofeedback with slow paced breathing)
Number of subjects: 0
Study 35761030 — intervention group
Group type: COMPARATOR
Intervention: Osc- condition (active control with little effect on heart rate oscillations)
Number of subjects: 0
Study 35761030 — intervention group
Group type: EXPERIMENTAL
Intervention: Osc+ condition
Number of subjects: 0
Study 33367742 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 450 IU HMG
Number of subjects: 114
Study 33367742 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) from Day 3 to 7 and 150 IU HMG
Number of subjects: 114
Study 33367742 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 450 IU HMG
Number of subjects: 114
Study 33367742 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 150 IU HMG
Number of subjects: 114
Study 33367742 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) and 450 IU HMG
Number of subjects: 114
Study 33367742 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg Clomiphene Citrate (CC) and 150 IU HMG
Number of subjects: 114
Study 33367742 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 114
Study 37745675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (≤2 mg/kg daily) in SLS I
Number of subjects: 300
Study 37745675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral mycophenolate mofetil (1500 mg twice daily) in SLS II
Number of subjects: 300
Study 37745675 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide (≤2 mg/kg daily) in SLS II
Number of subjects: 300
Study 37745675 — intervention group
Group type: COMPARATOR
Intervention: Active treatment groups pooled from SLS I and SLS II
Number of subjects: 300
Study 37745675 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS II
Number of subjects: 300
Study 37745675 — intervention group
Group type: EXPERIMENTAL
Intervention: SLS I
Number of subjects: 300
Study 34365645 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled regulation
Number of subjects: 39
Study 34365645 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous regulation
Number of subjects: 39
Study 32966294 — intervention group
Group type: EXPERIMENTAL
Intervention: Guardix‐SG®
Number of subjects: 83
Study 32966294 — intervention group
Group type: COMPARATOR
Intervention: Control (no Guardix‐SG®)
Number of subjects: 83
Study 35051151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (intraarticular O2-O3 mixture hip injections with ozonated autohemotherapy)
Number of subjects: 71
Study 35051151 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Number of subjects: 71
Study 35051151 — intervention group
Group type: COMPARATOR
Intervention: Control (protected weight bearing)
Number of subjects: 71
Study 34700600 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI-guided dose-painting radiotherapy (DP-RT)
Number of subjects: 186
Study 34700600 — intervention group
Group type: COMPARATOR
Intervention: CT-based radiotherapy
Number of subjects: 186
Study 32312010 — intervention group
Group type: EXPERIMENTAL
Intervention: HBO therapy (Group A)
Number of subjects: 30
Study 32312010 — intervention group
Group type: EXPERIMENTAL
Intervention: No HBO therapy (Group B)
Number of subjects: 30
Study 32312010 — intervention group
Group type: COMPARATOR
Intervention: Normal control (Group C)
Number of subjects: 30
Study 34687214 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimekizumab 320 mg at weeks 0/4, followed by bimekizumab 320 mg at week 16
Number of subjects: 49
Study 34687214 — intervention group
Group type: COMPARATOR
Intervention: Bimekizumab 320 mg at weeks 0/4, followed by placebo at week 16
Number of subjects: 49
Study 33685888 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard regimen (2.4 mg/kg body weight i.v. artesunate at 0 and 12 h)
Number of subjects: 94
Study 33685888 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified regimen (4 mg/kg i.v. artesunate at 0 h)
Number of subjects: 94
Study 32853275 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-conservation PR
Number of subjects: 176
Study 32853275 — intervention group
Group type: COMPARATOR
Intervention: Traditional PR
Number of subjects: 176
Study 34583525 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous mesenchymal stem cell (MSC) treatment
Number of subjects: 54
Study 34583525 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 54
Study 34425767 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent loneliness
Number of subjects: 224
Study 34425767 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent loneliness
Number of subjects: 224
Study 34425767 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent social isolation
Number of subjects: 224
Study 34425767 — intervention group
Group type: COMPARATOR
Intervention: Never lonely (reference group)
Number of subjects: 224
Study 34425767 — intervention group
Group type: COMPARATOR
Intervention: Not socially isolated (reference category)
Number of subjects: 224
Study 36209084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training + Vitamin D supplementation (AT+Vit D)
Number of subjects: 40
Study 36209084 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 40
Study 36209084 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (Vit D)
Number of subjects: 40
Study 36209084 — intervention group
Group type: COMPARATOR
Intervention: Control + Placebo (C)
Number of subjects: 40
Study 33413233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention consisting of 12 weekly sessions delivered in primary care settings and community assets.
Number of subjects: 390
Study 33413233 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based intervention.
Number of subjects: 390
Study 33413233 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG).
Number of subjects: 390
Study 32604296 — intervention group
Group type: EXPERIMENTAL
Intervention: New incision design (n = 24)
Number of subjects: 48
Study 32604296 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (n = 24)
Number of subjects: 48
Study 33902493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (8 sessions, 1 hour each) for parents or guardians
Number of subjects: 50
Study 33811980 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental variable analysis
Number of subjects: 0
Study 33811980 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 33167321 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-restricted eating (TRE)
Number of subjects: 20
Study 33167321 — intervention group
Group type: COMPARATOR
Intervention: Non-TRE
Number of subjects: 20
Study 35908457 — intervention group
Group type: EXPERIMENTAL
Intervention: oral conjugated equine estrogens (o‐CEE, n = 104)
Number of subjects: 374
Study 35908457 — intervention group
Group type: EXPERIMENTAL
Intervention: transdermal 17β‐estradiol (t‐E2, n = 119)
Number of subjects: 374
Study 35908457 — intervention group
Group type: COMPARATOR
Intervention: placebo (n = 115)
Number of subjects: 374
Study 33758944 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry consumption (2 × 25 g freeze-dried strawberry powder twice daily for 4 weeks)
Number of subjects: 34
Study 33758944 — intervention group
Group type: COMPARATOR
Intervention: Control beverage (energy-, volume-matched control powder for 4 weeks)
Number of subjects: 34
Study 35245224 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen Reserve Index (ORI) group
Number of subjects: 124
Study 35245224 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 124
Study 35245224 — intervention group
Group type: EXPERIMENTAL
Intervention: ORI group
Number of subjects: 124
Study 35245224 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 124
Study 32343288 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who continued in the trial
Number of subjects: 18
Study 32343288 — intervention group
Group type: COMPARATOR
Intervention: Patients who dropped out of the trial
Number of subjects: 18
Study 35476320 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine-assisted self-monitoring blood glucose (Group A)
Number of subjects: 123
Study 35476320 — intervention group
Group type: COMPARATOR
Intervention: Standard self-monitoring blood glucose (Group B)
Number of subjects: 123
Study 33481009 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-derived gene expression
Number of subjects: 1194
Study 33481009 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood analyses
Number of subjects: 1194
Study 33481009 — intervention group
Group type: EXPERIMENTAL
Intervention: FURIN locus
Number of subjects: 1194
Study 33481009 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC12A5 locus
Number of subjects: 1194
Study 36433709 — intervention group
Group type: EXPERIMENTAL
Intervention: Janagliflozin 25 mg
Number of subjects: 421
Study 36433709 — intervention group
Group type: EXPERIMENTAL
Intervention: Janagliflozin 50 mg
Number of subjects: 421
Study 36433709 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 421
Study 36433709 — intervention group
Group type: EXPERIMENTAL
Intervention: Janagliflozin 25 mg and 50 mg
Number of subjects: 421
Study 33434289 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-selection inference methods tailored toward changepoint detection using binary segmentation, wild and circular variants, and fused lasso.
Number of subjects: 0
Study 33434289 — intervention group
Group type: EXPERIMENTAL
Intervention: Markov chain Monte Carlo algorithms (importance sampling and hit-and-run sampling) used in tests.
Number of subjects: 0
Study 33443971 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 4401
Study 33443971 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 4401
Study 33378510 — intervention group
Group type: EXPERIMENTAL
Intervention: APC flash‐free brackets
Number of subjects: 30
Study 33378510 — intervention group
Group type: COMPARATOR
Intervention: Conventional ceramic brackets
Number of subjects: 30
Study 32171183 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied with a lymphatic correction technique in three-four day intervals for four weeks.
Number of subjects: 35
Study 32171183 — intervention group
Group type: COMPARATOR
Intervention: Compression garment (CG) worn daily for 23 hours.
Number of subjects: 35
Study 35594919 — intervention group
Group type: EXPERIMENTAL
Intervention: LASIK
Number of subjects: 40
Study 35594919 — intervention group
Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 40
Study 34157494 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 62
Study 34157494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no reflexology)
Number of subjects: 62
Study 32195805 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH treatment
Number of subjects: 60
Study 32195805 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 60
Study 36232995 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate Dialysate (1 mmol/L)
Number of subjects: 21
Study 36232995 — intervention group
Group type: COMPARATOR
Intervention: Acetate Dialysate (4 mmol/L)
Number of subjects: 21
Study 36482606 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with cisplatin and intraperitoneal perfusion with rmhTNF‐NC
Number of subjects: 20
Study 32447722 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab treatment
Number of subjects: 35
Study 33113783 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvacrol (100%, 75%, and 50%)
Number of subjects: 42
Study 33113783 — intervention group
Group type: COMPARATOR
Intervention: Control drug (10% ethanol)
Number of subjects: 42
Study 36078234 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-Square Step Exercises (NSSE) for at least 45 days over 8 weeks
Number of subjects: 46
Study 33556067 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing clinical compression socks (20-30 mmHg)
Number of subjects: 26
Study 33556067 — intervention group
Group type: COMPARATOR
Intervention: Wearing non-clinical compression socks (< 20 mmHg)
Number of subjects: 26
Study 33556067 — intervention group
Group type: COMPARATOR
Intervention: Wearing normal socks
Number of subjects: 26
Study 33556067 — intervention group
Group type: COMPARATOR
Intervention: Barefoot
Number of subjects: 26
Study 32847838 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (60 mg daily)
Number of subjects: 495
Study 32847838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 495
Study 35966245 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G minimally invasive vitrectomy combined with glaucoma drainage valve implantation
Number of subjects: 83
Study 35966245 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G minimally invasive vitrectomy combined with phacoemulsification cataract extraction
Number of subjects: 83
Study 35966245 — intervention group
Group type: COMPARATOR
Intervention: 23G minimally invasive vitrectomy combined with glaucoma drainage valve implantation and phacoemulsification cataract extraction
Number of subjects: 83
Study 33744668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing IDPE alone
Number of subjects: 252
Study 33744668 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharing needles with or without IDPE
Number of subjects: 252
Study 33744668 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SSTI
Number of subjects: 252
Study 35084634 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional platelet-rich plasma (PRP) injection
Number of subjects: 30
Study 35084634 — intervention group
Group type: COMPARATOR
Intervention: 1064 nm long-pulsed Nd:YAG laser
Number of subjects: 30
Study 35950601 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic (test) edoxaban 60-mg tablet in fasting condition
Number of subjects: 64
Study 35950601 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic (test) edoxaban 60-mg tablet in fed condition
Number of subjects: 64
Study 35950601 — intervention group
Group type: COMPARATOR
Intervention: Branded (reference) edoxaban 60-mg tablet in fasting condition
Number of subjects: 64
Study 35950601 — intervention group
Group type: COMPARATOR
Intervention: Branded (reference) edoxaban 60-mg tablet in fed condition
Number of subjects: 64
Study 33563752 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 0
Study 33563752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with FGFR and MEK inhibitors
Number of subjects: 0
Study 33563752 — intervention group
Group type: EXPERIMENTAL
Intervention: FGFR-specific inhibitors (BGJ398, erdafitinib, TAS-120)
Number of subjects: 0
Study 33563752 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33372072 — intervention group
Group type: EXPERIMENTAL
Intervention: Carnosine supplementation for 12 weeks
Number of subjects: 240
Study 33372072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 32969040 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed loop automated oxygen control system
Number of subjects: 24
Study 32969040 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study 36079874 — intervention group
Group type: EXPERIMENTAL
Intervention: Early standardized lunch at 12:00 (12S)
Number of subjects: 26
Study 36079874 — intervention group
Group type: EXPERIMENTAL
Intervention: Late standardized lunch at 14:00 (14S)
Number of subjects: 26
Study 36079874 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple preload to early standardized lunch (12A+S)
Number of subjects: 26
Study 36079874 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple preload to late standardized lunch (14A+S)
Number of subjects: 26
Study 32668456 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg albendazole
Number of subjects: 466
Study 32668456 — intervention group
Group type: COMPARATOR
Intervention: 200 mg albendazole
Number of subjects: 466
Study 32668456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study 32641091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate treatment for no more than 10 days
Number of subjects: 0
Study 32641091 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir treatment for no more than 10 days
Number of subjects: 0
Study 32641091 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate treatment
Number of subjects: 0
Study 36155062 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g% MSG in drinking water
Number of subjects: 40
Study 36155062 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g% MSG in drinking water
Number of subjects: 40
Study 36155062 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g% MSG in drinking water
Number of subjects: 40
Study 36155062 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0 g% MSG in drinking water (withdrawn after 4 weeks)
Number of subjects: 40
Study 36155062 — intervention group
Group type: COMPARATOR
Intervention: Standard diet (control group)
Number of subjects: 40
Study 33781103 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75mg or 125mg)
Number of subjects: 194